Akari released interim results from a Phase Ib dose-ranging study of Coversin in healthy volunteers. The trial was a double-blind, placebo-controlled study with six participants and showed complete inhibition of complement activity in the four patients on the active arm, receiving 30mg of Coversin dosed twice daily for two days followed by once daily for five days. The Phase Ib trial is designed to continue to other doses; the company stated that it will proceed with Phase II studies using th
08 Jul 2016
Increasing evidence of Coversin activity
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Increasing evidence of Coversin activity
- Published:
08 Jul 2016 -
Author:
Maxim Jacobs -
Pages:
5
Akari released interim results from a Phase Ib dose-ranging study of Coversin in healthy volunteers. The trial was a double-blind, placebo-controlled study with six participants and showed complete inhibition of complement activity in the four patients on the active arm, receiving 30mg of Coversin dosed twice daily for two days followed by once daily for five days. The Phase Ib trial is designed to continue to other doses; the company stated that it will proceed with Phase II studies using th